Thomas Grader‐Beck

Performance characteristics of an electronic medical record alert system to identify hospitalised patients with active hepatitis C virus infection: a cross-sectional analysis from two large academic centres

Patrick F. Pryal, Walid G. El-Nahal, Kelly Gebo, Thomas Grader‐Beck et autres

OBJECTIVES: Direct-acting antivirals are highly effective in curing hepatitis C virus (HCV) infection but linkage to care remains a barrier to population-wide treatment. Hospitalisation for any cause may be an opportunity to identify candidates for treatment. Here, we present the test characteristics …

us (code pays fourni par la source)

OMERACT- determining a core domain set for Sjögren’s disease: International focus group series

Dana DiRenzo, Lee Ang, Caroline O’Brien, Adrian Lee et autres

BACKGROUND: Sjögren's Disease (SjD) is a systemic autoimmune disease that is associated with a significant reduction in health-related quality of life (HRQoL). The goal of this study was to better understand HRQoL using a multi-national and rigorously defined SjD population according to …

us, au, in, cn, gb, fr, nl (code pays fourni par la source)

EE297 ECONOMIC BURDEN ASSOCIATED WITH SJÖGREN’S DISEASE (SJD): A SYSTEMATIC LITERATURE REVIEW (SLR)

Thomas Grader‐Beck, Dana DiRenzo, Anjana Lalla, Shweta Takyar et autres

us, in (code pays fourni par la source)

PCR110 UNDERSTANDING THE HUMANISTIC BURDEN OF SJÖGREN’S DISEASE (SJD): A SYSTEMATIC LITERATURE REVIEW (SLR)

Thomas Grader‐Beck, Dana DiRenzo, Anjana Lalla, Shweta Takyar et autres

us, in (code pays fourni par la source)

Clinical trials and new therapies in Sjögren’s disease

Vishal Patel, Antonio Salas, Thomas Grader‐Beck

Despite major advances in understanding Sjögren's disease (SjD), no approved disease-modifying therapies have been approved. Management remains largely symptomatic with the use of off-label immunomodulators for systemic features. This gap highlights the substantial unmet need for targeted treatment. Encouragingly, the therapeutic landscape …

us (code pays fourni par la source)

Sjogren’s Disease Evaluation and Monitoring Scoping Review

Donald Thomas, Katherine M. Hammitt, Julie Frantsve‐Hawley, Esen K. Akpek et autres

Le Ianalumab démontre une réduction significative de l’activité de la maladie chez les patients atteints de la maladie de Sjögren : résultats d’efficacité et de tolérance issue de deux études internationales de phase 3 (NEPTUNUS-1 et NEPTUNUS-2)

Xavier Mariette, Thomas Grader‐Beck, Stephanie Finzel, Elena Schiopu et autres

Les anticorps préexistants contre les antigènes vaccinaux sont conservés chez des patients atteints de la maladie de Sjögren et de lupus érythémateux systémique lors du traitement par ianalumab, alors que les auto-anticorps diminuent

Eric J. Lazaro, Thomas Dörner, N. Shen, Thomas Grader‐Beck et autres

fr, de, cn, us, ch (code pays fourni par la source)

Le ianalumab démontre une réduction significative de l’activité de la maladie chez les patients atteints de la maladie de Sjögren : résultats d’efficacité et de tolérance issus de deux études internationales de phase 3 (NEPTUNUS-1 et NEPTUNUS-2)

Xavier Mariette, Thomas Grader‐Beck, Stephanie Finzel, Elena Schiopu et autres

Ophthalmologic Involvement in Sjögren's Disease

Anna Flts, Esen K. Akpek, Thomas Grader‐Beck

Sjögren’s disease, an autoimmune condition commonly characterized by dry eye and dry mouth, remains significantly underappreciated, underdiagnosed, and undertreated. Given the complex nature of the disease, clinical course, and vast array of symptoms, understanding the early presentation of the disease is key …

POS0683 PREEXISTING ANTIBODIES AGAINST VACCINE ANTIGENS ARE PRESERVED IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND SJÖGREN'S DISEASE UPON IANALUMAB TREATMENT WHILE AUTOANTIBODIES DECLINE

Thomas Dörner, Nan Shen, Thomas Grader‐Beck, Caroline Walter et autres

Background: Ianalumab, an afucosylated monoclonal antibody, depletes B cells through enhanced antibody-dependent cellular cytotoxicity with concurrent blockade of signals mediated by B-cell–activating factor (BAFF):BAFF receptor (BAFF-R) [1]. It is currently being investigated for the treatment of immune-mediated diseases. Given its novel mechanism …

de, cn, us, ch (code pays fourni par la source)

POS0844 EFFICACY AND SAFETY OF EFGARTIGIMOD PH20 SUBCUTANEOUS BY PREFILLED SYRINGE IN ADULTS WITH PRIMARY SJÖGREN'S DISEASE: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL WITH OPEN-LABEL EXTENSION (UNITY)

Isabelle Peene, Xavier Mariette, D. Elewaut, Thomas Dörner et autres

Background: Primary Sjögren's disease (pSjD) is a chronic, progressive, autoimmune disease, characterized by lymphocytic infiltration and progressive destruction of the exocrine glands. B-cell activation plays a pivotal role in the development of the disease, resulting in the production of immunoglobulin (Ig) G, …

be, fr, de, nl, us, ie, gb (code pays fourni par la source)